HR 6000 117th Congress House Health Administrative law and regulatory procedures Administrative remedies Advisory bodies Appropriations Cardiovascular and respiratory health Cell biology and embryology Centers for Disease Control and Prevention (CDC) Child care and development Child health Computers and information technology Congressional oversight Department of Health and Human Services Digestive and metabolic diseases Digital media Drug safety, medical device, and laboratory regulation Drug therapy Economic performance and conditions Education programs funding Emergency medical services and trauma care

Cures 2.0 Act

Introduced: November 17, 2021 Introduced by: DeGette, Diana Democratic · Colorado See on congress.gov

Everywhere this bill has been 8 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Jan 4, 2022

Referred to the Subcommittee on Biotechnology, Horticulture, and Research.

Dec 7, 2021

Referred to the Subcommittee on Health.

Dec 2, 2021

Referred to the Subcommittee for Indigenous Peoples of the United States.

Nov 18, 2021

Referred to the Subcommittee on Oversight, Management, and Accountability.

Nov 18, 2021

Referred to the Subcommittee on Health.

Nov 17, 2021

Referred to the Subcommittee on Health.

Nov 17, 2021

Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, the Budget, Science, Space, and Technology, Agriculture, Education and Labor, Armed Services, Natural Resources, Veterans' Affairs, Homeland Security, and the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Nov 17, 2021

Introduced in House

Plain-English summary Congressional Research Service

Cures 2.0 Act

This bill addresses pandemic preparedness and public health issues, caregiver and patient engagement, drug development, insurance coverage, and biomedical research.

The Department of Health and Human Services (HHS) must undertake research and other activities concerning COVID-19 and develop a strategy for future pandemics and declared emergencies. Additionally, the bill specifies actions to combat antimicrobial resistance.

HHS may award grants for caregiver training. The bill also addresses diversity in clinical trials, collecting patient experience data during clinical trials, and coverage for care related to participation in specified clinical trials.

The bill modifies the timeframe and requires additional guidance relating to expedited approval of certain breakthrough drugs, devices, or products. It also establishes two intercenter institutes within the Food and Drug Administration (FDA) focused on particular diseases that meet specified criteria.

The bill also addresses (1) coverage in Medicare, Medicaid, and the Children's Health Insurance Program for telehealth, genetic and genomic testing, and other services; (2) electronic prescribing standards for Medicare drug benefits; and (3) access to Medicare and Medicaid claims data by certain registries. Furthermore, the bill prohibits the use of geographic tracking or biometrics in Medicaid electronic visit verification systems.

The bill establishes the Advanced Research Projects Agency for Health (ARPA-H) within the National Institutes of Health to accelerate biomedical research and innovation through grants, contracts, cash prizes, and other means. The FDA may work with ARPA-H to expedite the development of medical products through specified activities.

What's happening now January 4, 2022

Referred to the Subcommittee on Biotechnology, Horticulture, and Research.

Committees of jurisdiction 17